301015.SZShenzhen
Qingdao Baheal Medical INC.
¥21.20
ListedJun 30, 2021
SectorHealthcare
IndustryMedical Distribution
CountryChina
Employees2493
State-| CityQingdao| AddressNo. 88, Kaifeng Road| Phone86 53 26675 6688
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin and Xospata brand names; anti-aging and cosmeceuticals under the Quanis, Excellula, TRANSINO, and Qingchunbao brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; respiratory and anti-infective products under the Klacid brand name; and medical nutrition under the Nutrasumma brand name. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of BAHEAL Pharmaceutical Holdings Limited.

Key Indicators

Key financial and dividend metrics for this stock.

?
P/E Ratio
23.3
?
Div. Rate
¥0.57
?
Div. Yield
2.55%
?
Payout Ratio
79.38%
?
Max Consec. Div. Years
4 years
?
Longest Consec. Div.
4 years
?
Div. Coverage
100%
?
Div. Stability Rate
0.06
?
Div. Growth Rate
33.00%
?
Score
85

Dividend History

Historical dividend payments by ex-dividend date.

Jun 1, 2026
¥ 0.5710
May 27, 2025
¥ 0.7620
May 29, 2024
¥ 0.7620
May 25, 2023
¥ 0.7620
May 25, 2022
¥ 0.6670

Peer Companies

Other stocks in the same sector.

The app download will be available in the next version. Stay tuned!